Parenteral Manual


Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Antipsychotic, antianxiety, sedative
Original Date: 
August 2005
Revised Date: 
January 2010
  • Psychosis, delirium, disruptive behaviour, anxiety
  • Vomiting
  • Pain
Reconstitution and Stability: 
  • Available as a 25 mg/mL injection. Store at room temperature   
  • Protect from light - discard markedly discoloured solutions 

- Solutions Compatible: D5W, 0.9% NaCl

- Additives/Above Cassette Compatible: perphenazine, hydroxyzine (for 15 minutes); atropine, scopolamine

-Y-site Compatible: no information

-Incompatible: heparin, ranitidine 


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

SC NO, not recommended due to local irritation

YES, deep into large muscle; rotate injection sites
Usual dilution: undiluted

IV Direct NO
IV Intermittent Infusion

YES, blood pressure monitoring
Usual dilution: 0.2 mg/mL
Infusion time: 20-30 minutes

IV Continuous Infusion NO

(For neonatal dosages, refer to Neonatal IV Drug Manual.)


  • Palliative Care: starting doses 0.2 mg/kg IV Q4H PRN  Max 10 mg/dose
  • Maximum dose 0.4 mg/kg/dose  Max 10 mg/dose
Potential hazards of parenteral administration: 
  • Decreased BP presenting as dizziness, fainting, syncope or weakness.  Usually occurs within 10-20 minutes following IM injections and can last up to 12 hours
  • Orthostatic hypotension
  • Pain at injection site, dermatitis
  • Tachycardia or bradycardia, arrhythmias
  • Extrapyramidal effects, grand mal seizures
  • Disorientation, excessive sedation, slurring of speech
  • Nausea, vomiting, abdominal discomfort
  • Contraindicated in patients with severe cardiac, hepatic or renal disease, in the presence of overdose of CNS depressants or comatose states
  • May potentiate the action of other CNS depressants (barbiturates, analgesics, narcotics, antihistamines); dose reductions are suggested during concomitant use.
  • Because orthostatic hypotension may be encountered at the start of treatment, keep patient supine for 6-12 hours after initial dose

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.